We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2024
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Revolutionary Blood Test to Transform Early Diagnosis of Bowel Cancer

By LabMedica International staff writers
Posted on 20 May 2022

Bowel (colorectal) cancer is the second most common cancer globally. It is the leading cause of cancer-related death in the Western world. Early diagnosis of bowel cancer significantly reduces mortality rate. Current diagnostics tests such as colonoscopy or fecal blood detection kits can be invasive, unpleasant and expensive. Now, an accurate, non-invasive, inexpensive blood test can diagnose bowel cancer early and dramatically cut waiting times for diagnosis while reducing the need for unnecessary invasive procedures such as colonoscopies.

Researchers at Swansea University (Swansea, UK) have devised a simple Raman Spectrometry (RS) blood test which can return test results in under 20 minutes. Using innovations based around laser spectroscopy and artificial intelligence (AI) -based analytics, the test analyses cancer-driven metabolic activity in blood that their AI software is trained to interpret and diagnose. The test aims to break down patient anxiety with a highly accurate test to give rapid reassurance to those who have not got cancer and ensure they do not need an invasive colonoscopy. As a result, this will free up valuable endoscopy and colonoscopy resource and speed up treatment for those who have cancer while resulting in savings from a reduction of needless colonoscopies.


Image: Accurate, non-invasive, inexpensive blood test will help diagnose bowel cancer early (Photo courtesy of Swansea University)
Image: Accurate, non-invasive, inexpensive blood test will help diagnose bowel cancer early (Photo courtesy of Swansea University)

Results from a ground-breaking study involving 27 practices and 595 patients showed 79% of early-stage bowel cancers and 100% of advanced bowel cancers were picked up by the test. Early comparisons with other tests currently available in primary care have shown the RS blood test to have greater sensitivity for the detection of bowel cancer. Currently, a high number of unnecessary colonoscopies are conducted to ensure cases of bowel cancer are detected. Since the start of the pandemic, waiting lists for the procedure have significantly increased. These delays can reduce the chances of patient survival, with many people being diagnosed too late. The blood test hopes to change all that by providing accurate results within 48 hours, preventing unnecessary colonoscopies and relieving pressure on healthcare systems.

Related Links:
Swansea University 


New
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Urine Collection Container
Urine Monovette
New
Adenovirus Detection Kit
REALQUALITY RQ-ADENO

Latest Molecular Diagnostics News

Single Metagenomic Next-Generation Sequencing Test Can Detect All Infectious Pathogens

Cutting-Edge Diagnostic Tool Rapidly Identifies Emerging SARS-CoV-2 Variants

Novel Method Analyzes Genetic Variations in Families with High Incidence of Breast Cancer